Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
David V Morrissey(Mirna Therapeutics (United States)), Jennifer A. Lockridge(Mirna Therapeutics (United States)), Lucinda Shaw(Mirna Therapeutics (United States)), Karin S. Blanchard(Mirna Therapeutics (United States)), Kristi Jensen(Mirna Therapeutics (United States)), Wendy Breen(Mirna Therapeutics (United States)), Kimberly Hartsough(Mirna Therapeutics (United States)), Lynn Machemer(Mirna Therapeutics (United States)), Susan F. Radka(Mirna Therapeutics (United States)), Vasant Jadhav(Mirna Therapeutics (United States)), Narendra K. Vaish(Mirna Therapeutics (United States)), Shawn Zinnen(Mirna Therapeutics (United States)), Chandra Vargeese(Mirna Therapeutics (United States)), Keith Bowman(Mirna Therapeutics (United States)), Chris S. Shaffer(Mirna Therapeutics (United States)), Lloyd B. Jeffs, Adam D. Judge, Ian MacLachlan, Barry Polisky(Mirna Therapeutics (United States))
Cited by 1,162
Abstract
Related Papers
No related papers found
Powered by citation graph analysis